by Tom Lillig, Vice President, General Manager, Software Informatics Division, Agilent and Paul Hofstadler, Vice President, General Manager, Digital Services Enablement Division, Agilent
The demand for faster turnaround times and quicker results in the pharma and biopharma space has been a key challenge for many laboratories. According to an Agilent survey of global pharma lab leaders conducted before the pandemic, 83% of respondents stated that their processes required optimization to keep up with demand.1 This pressure was intensified by the pandemic, which accelerated the digital transformation of a wide range of industries, including healthcare and life sciences.
As a result, there is a growing expectation that drug research and development (R&D) should now be able to be achieved at an advanced rate, but this adds additional operational stresses on laboratories and potentially other stakeholders associated with getting a drug product through to the market. Fortunately, advances in lab automation and digitization are resulting in significant improvements across the pharmaceutical industry. An exemplary area where this can be seen is the development of novel drug candidates.
Read more on Labcompare.